Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

lly well tolerated in the study.(1) A small number of patients discontinued due to adverse events.(1)

"The impressive rates of response observed in this study, combined with the very low rate of disease progression seen in nilotinib-treated patients are very encouraging," said Professor Richard Clark, Consultant Haematologist at Royal Liverpool University Hospital and a trialist involved in this study. "Continued improvement in the treatment of Ph+ CML is very important and these results indicate that nilotinib may provide long-term improvement in progression-free survival."

95% of patients with CML have an abnormality known as the Philadelphia chromosome. This chromosome produces a type of protein called Bcr-Abl, which is responsible for the overproduction of the cancerous white blood cells that are the main feature in Ph+ CML.(3) Nilotinib is a potent and selective inhibitor of the Bcr-Abl protein, thereby inhibiting the production of these cancerous cells.(4,5)

"Novartis has been at the forefront of research on the molecular origin of Ph+ CML and this has led to the development of treatments with unprecedented effectiveness and safety," said Panos Alexakos, Oncology Business Unit Head for Novartis UK. "These data are exciting and the deeper molecular response demonstrated provides hope for further improvement in outcomes for patients with Ph+ CML in the future."

Novartis plans to file worldwide applications for approval of nilotinib as a treatment for adult patients with newly diagnosed Ph+ CML. Nilotinib is currently approved in more than 80 countries including the European Union (EU), United States and other countries for the treatment of adult patients with Ph+ CML in chronic phase or accelerated phase who are resistant or intolerant to prior treatment including imatinib.

Notes to editors

Study details

The clinical trial, Evaluating Nilot
'/>"/>

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015   PDI , ... today announced a series of corporate commitments designed ... to reduce the threat of antimicrobial-resistant microorganisms as ... Centers for Disease Control and Prevention (CDC) and ... to Combat Antibiotic-Resistant Bacteria. Along with ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( ... PharmaBiotech,s new report "Drug Delivery in Central ... to their offering. The delivery ... a challenge in the treatment of neurological disorders. ... or administered systematically (e.g., by intravenous injection) for ...
(Date:6/2/2015)... , June 2, 2015 The Canadian Society ... of specific tests, treatments or procedures that are ... Surgery as part of Choosing Wisely Canada.  The ... can support conversations between patients and physicians about ... Canadian Society for Vascular Surgery,s list identified the ...
Breaking Medicine Technology:PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4
... from PI-88 in Liver Cancer and ... Highlight the Year -, SYDNEY, Australia, Aug. 23 ... for the fiscal year ended 30 June 2007. Fiscal ... Phase 2, 172 patient, post-resection liver cancer trial for ...
... Incorporated (Nasdaq:,VICL) announced today that results from a ... a plasmid DNA (pDNA) vaccine developed by the ... previously,reported Phase 1 conclusions that a "DNA prime-adenoviral ... was effective in inducing,T-cell immune responses in up ...
Cached Medicine Technology:Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3
(Date:6/2/2015)... June 02, 2015 The Down Syndrome ... Potter from the hit show Glee as the keynote ... Walk in Pleasant Prairie, WI. The event aims to ... in Racine, Kenosha, and Walworth counties. ... join us for this important event," says Dawn Nuoffer, ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... replacement lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is now underway ... to court documents, opening statements were presented on ... laser etchings on the Profemur hip replacement made ... it to snap just three years after it ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Tronics, a ... deploying its growth strategy to benefit from the significant ... Yole Développement’s May 2015 Status of the MEMS Industry ... sharply and reach $6.6B in 2020,” says Frederic Breussin, ... Développement . , The analyst adds that “although the ...
(Date:6/2/2015)... June 02, 2015 ANT Wireless, proven ... market entry of two new products implementing the ANT+ ... announce new wireless interoperability in their bike trainer products, ... cyclists. Tacx has implemented the FE-C device profile in ... well as its new indoor training software, while Kinomap ...
(Date:6/2/2015)... Acara Partners has seen a spike in ... mobile devices, as is now required by recent Google search ... well as several new clients in the medical aesthetics vertical, ... them to meet Google’s new requirements,” commented Fran Acunzo, CEO ... clients in education, non-profits, and the business world.” , ...
Breaking Medicine News(10 mins):Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:Acara Partners Expands Website and Digital Offerings 2
... University is investigating the molecular composition of cataracts in ... reverse the eye disease. Cataracts, a clouding of ... in the world, according to the National Institutes of ... eye lens is the only recommended method for restoring ...
... July 14 The Empire State Healthcare Coalition expresses its ... national, government-run health plan to compete with private insurers. ... eliminate free market efficiency and reduce healthcare quality. , ... (the "Coalition") is not-for-profit organization formed by New York State ...
... ... the Pederson Immigration Law Group, P.C. is slated to be keynote speaker at this ... ... - The Pederson Immigration Law Group, P.C., (PILG) announced that Jan Pederson, the nation,s ...
... published in the July issue of the Journal of ... with gastrointestinal stromal tumors (GIST), a rare cancer that begins ... rates equivalent to those of Caucasians. Prior to 2000, African ... to undergo surgical treatment for this type of cancer. ...
... , KUALA LUMPUR, Malaysia, July 14 Ramuan ... from ancient Malaysian culture, will be revealed to a global audience ... new book, Health and Beauty from the Rainforest: Malaysian Traditions ... by these traditions. A lifestyle approach to wellness, ramuan ...
... , , MINNEAPOLIS, July 14 ... advised Biotel that it is terminating the Merger Agreement with ... terms of the agreement. Biotel believes it has complied with ... merit and inconsistent with CardioNet,s representations to Biotel. Biotel is ...
Cached Medicine News:Health News:K-State scientist receives grant from National Institutes of Health to research cataracts 2Health News:The Empire State Healthcare Coalition Voices Concern Over the Affordable Health Choices Act 2Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 2Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 3Health News:Study finds survival rates from gastrointestinal tumors improving among African-Americans 2Health News:U.S. Debut: Holistic Health And Beauty From The Rainforest - New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the World to Time-Honored Tradition of Ramuan 2Health News:U.S. Debut: Holistic Health And Beauty From The Rainforest - New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the World to Time-Honored Tradition of Ramuan 3
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... accurate detections of any ... as glaucoma in the ... performed. Smooth operation of ... High accuracy of static ...
... in visual field testing that's so efficient it ... the first visual field instrument that's simple enough, ... even in pre-test. Affordably priced FDT has years ... validate performance. The instrument produce screening results in ...
... The Humphrey Matrix represents the ... Using frequency doubling technology, the Humphrey ... thorough visual field evaluation and assess ... enables you to provide complete long-term ...
Medicine Products: